Literature DB >> 910459

Arterial epigastricocavernous anastomosis for the treatment of sexual impotence.

V Michal, R Kramár, J Pospíchal, L Hejhal.   

Abstract

Entities:  

Mesh:

Year:  1977        PMID: 910459     DOI: 10.1007/bf01565928

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


× No keyword cloud information.
  5 in total

1.  VENOUS BYPASS TO CONTROL PRIAPISM.

Authors:  J T GRAYHACK; W MCCULLOUGH; V J O'CONOR; O TRIPPEL
Journal:  Invest Urol       Date:  1964-03

2.  MECHANISM OF HUMAN PENILE ERECTION.

Authors:  H F NEWMAN; J D NORTHUP; J DEVLIN
Journal:  Invest Urol       Date:  1964-01

3.  [Penile arterial occlusions in erection impotence. A new type of angiography-phalloarteriography].

Authors:  V Michal; J Pospíchal; M Lachman
Journal:  Cas Lek Cesk       Date:  1976-10-08

4.  Femoro-pudendal by-pass, internal iliac thromboendarterectomy and direct arterial anastomosis to the cavernous body in the treatment of erectile impotence.

Authors:  V Michal; R Kramár; J Pospíchal
Journal:  Bull Soc Int Chir       Date:  1974 Jul-Aug

5.  [Direct arterial anastomosis on corpora cavernosa penis in the therapy of erective impotence].

Authors:  V Michal; R Kramár; J Pospíchal; L Hejhal
Journal:  Rozhl Chir       Date:  1973-09
  5 in total
  4 in total

1.  Phalloarteriography in the diagnosis of erectile impotence.

Authors:  V Michal; J Pospíchal
Journal:  World J Surg       Date:  1978-03       Impact factor: 3.352

2.  Glans ischemia after penis revascularization: therapeutic embolization.

Authors:  G Wilms; R Oyen; L Claes; W Boeckx; A L Baert; L Baert
Journal:  Cardiovasc Intervent Radiol       Date:  1990 Oct-Nov       Impact factor: 2.740

3.  Penile revascularization in the treatment of impotence.

Authors:  I D Sharlip
Journal:  West J Med       Date:  1981-03

Review 4.  Transluminal angioplasty in the treatment of arteriogenic impotence.

Authors:  K Valji; J J Bookstein
Journal:  Cardiovasc Intervent Radiol       Date:  1988-08       Impact factor: 2.740

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.